BCG (50mg/instillation) + N-803 (400 μg/instillation)
CA-ALT-803-01-14; QUILT-2.005
Phase 2 mab active
Quick answer
BCG (50mg/instillation) + N-803 (400 μg/instillation) for Non-muscle Invasive Bladder Cancer is a Phase 2 program (mab) at Immunitybio Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Immunitybio Ireland Limited
- Indication
- Non-muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- active